In which diseases is EzPAP (positive airway pressure for airway clearance) indicated, and should it be used alone or is it more effective when combined with short‑acting bronchodilators such as albuterol or ipratropium?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

EzPAP Indications and Use with Bronchodilators

EzPAP is indicated for COPD with emphysema and dynamic hyperinflation, and for postoperative hypoxemia/atelectasis, and should be used alone as a standalone therapy without requiring bronchodilators, though combining with bronchodilators is not contraindicated.

Disease Indications

EzPAP has demonstrated efficacy in three primary clinical scenarios:

1. COPD with Emphysema and Dynamic Hyperinflation

The device specifically targets patients with severe COPD and emphysema experiencing dynamic hyperinflation 1. In these patients, EzPAP reduces air-trapping through its combined inspiratory support (via Coanda effect) and expiratory positive pressure. Clinical outcomes include:

  • Reduced ventilator dependency
  • Median decrease in dyspnea by 3.3 points on the Borg scale
  • Improved 6-minute walk distance by 50.4 meters
  • Median vital capacity increase of 544 mL
  • Reduction in transcutaneous CO₂ by 7.3 mmHg 1

2. Hypercapnic COPD Exacerbations

For mild to moderate hypercapnic COPD exacerbations, EzPAP performs comparably or superior to non-invasive ventilation (NIV) 2. The device showed:

  • Significantly greater pH improvement compared to NIV (p=0.003)
  • Faster correction of respiratory acidosis at 1 and 4 hours
  • Significant PaO₂ improvement at 24 hours
  • More rapid resolution of hypercapnia

3. Postoperative Hypoxemia

In the recovery room setting, EzPAP effectively treats postoperative hypoxemia, particularly in high-risk patients 3. Benefits include:

  • Less frequent need to restart oxygen therapy (25 vs 41 patients, p=0.03)
  • Fewer postoperative complications (13 vs 25 patients, p=0.02)
  • Zero cases of nosocomial pneumonia (vs 4 in control group)
  • Particularly effective in obese patients and those with chronic lung disease

Standalone vs. Combined Use with Bronchodilators

EzPAP functions effectively as monotherapy and does not require bronchodilators for efficacy. The evidence base shows:

Standalone Efficacy

All clinical studies demonstrating EzPAP's benefits used the device as standalone therapy without mandatory bronchodilator co-administration 2, 1, 3. The device's mechanism—providing positive inspiratory and expiratory pressures to increase lung volumes and reduce dynamic hyperinflation—is mechanical rather than pharmacological 4.

Bronchodilator Combination Considerations

While EzPAP doesn't require bronchodilators, the broader positive expiratory pressure (PEP) literature provides relevant context. For traditional PEP devices in COPD/chronic bronchitis, studies show:

  • PEP combined with bronchodilators (ipratropium, albuterol) produced "significant additional improvement" in FEV₁ and FVC compared to bronchodilators alone 5
  • Combined therapy extended the median duration of 15% FEV₁ improvement to 5-7 hours versus 3-4 hours with beta-agonist alone 5

However, ipratropium as monotherapy is FDA-approved for maintenance treatment of COPD bronchospasm 5, and its combination with beta-agonists "has not been shown to be more effective than either drug alone in reversing bronchospasm associated with acute COPD exacerbation" 5.

Clinical Algorithm

Use EzPAP alone when:

  • Treating dynamic hyperinflation in severe COPD/emphysema
  • Managing mild-moderate hypercapnic COPD exacerbations
  • Addressing postoperative hypoxemia, especially in obese or pulmonary disease patients

Consider adding bronchodilators when:

  • Patient has concurrent bronchospasm requiring maintenance therapy
  • Seeking to extend duration of bronchodilation effect
  • Patient is already on established bronchodilator regimen for COPD management

Important Caveats

Flow settings matter significantly. EzPAP produces dose-dependent effects, with higher flows (13-15 L/min) generating peak expiratory pressures of 15 cmH₂O and end-expiratory pressures of 13 cmH₂O 4. Start at lower flows and titrate based on patient tolerance and therapeutic goals.

Not for all COPD patients. One study found that EPAP during exercise in COPD increased dyspnea, thoracoabdominal asynchrony, and reduced exercise tolerance without improving dynamic hyperinflation 6. This suggests EzPAP is best suited for resting therapy or specific clinical scenarios (exacerbations, postoperative) rather than during active exercise.

Patient selection is critical. The device showed particular benefit in patients with obesity and pulmonary disorders, achieving higher postoperative oxygen saturations than preoperative values 3. However, patients with heart failure showed no differential benefit compared to standard oxygen therapy 3.

References

4
Research

Effect of the EzPAP system on tidal volume and airway pressures in healthy adults.

Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR, 2026

Related Questions

Does the medical literature support the use of the EzPAP (positive airway pressure) system to improve lung expansion and prevent adverse clinical outcomes or exacerbations of comorbidities?
Is the EzPAP (positive airway pressure) system an effective preventive treatment for all residents in skilled‑nursing or long‑term‑care facilities regardless of diagnosis?
Is it appropriate to prescribe EzPAP (EzPAP device) for all residents in a skilled‑nursing or long‑term‑care facility as a blanket preventive measure regardless of diagnosis, and can it be billed under Medicare Part A?
Should EzPAP be used in patients with asthma who are stable on room air and have minimal or no symptoms?
Should I prescribe the EzPAP (positive expiratory pressure) device for all patients in my chronic tracheostomy and ventilator unit, given that most have hypoxic brain injury or stroke and only a few have neuromuscular respiratory failure or COPD, and can I bill Medicare for its use as a wellness program?
What is the CPT code for a robot-assisted minimally invasive Ivor Lewis esophagectomy performed for distal esophageal adenocarcinoma in a patient on postoperative day 3?
What conditions cause leukopenia and thrombocytopenia with normal hemoglobin and hematocrit?
Is my leg pain due to a vascular condition such as superficial venous insufficiency?
Can you prescribe vitamin D3?
What is the recommended Medrol (methylprednisolone) dose pack regimen for treating acute severe migraine (status migrainosus)?
How can I prescribe vitamin D3 (cholecalciferol) if it is not listed in my electronic medical record?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.